GB202107706D0 - Combination therapy - Google Patents
Combination therapyInfo
- Publication number
- GB202107706D0 GB202107706D0 GBGB2107706.0A GB202107706A GB202107706D0 GB 202107706 D0 GB202107706 D0 GB 202107706D0 GB 202107706 A GB202107706 A GB 202107706A GB 202107706 D0 GB202107706 D0 GB 202107706D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- combination therapy
- therapy
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000002648 combination therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2107706.0A GB202107706D0 (en) | 2021-05-28 | 2021-05-28 | Combination therapy |
| PCT/EP2022/063158 WO2022248268A1 (en) | 2021-05-28 | 2022-05-16 | Combination therapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2107706.0A GB202107706D0 (en) | 2021-05-28 | 2021-05-28 | Combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202107706D0 true GB202107706D0 (en) | 2021-07-14 |
Family
ID=76741178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2107706.0A Ceased GB202107706D0 (en) | 2021-05-28 | 2021-05-28 | Combination therapy |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB202107706D0 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO2007044515A1 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Azetidines as mek inhibitors for the treatment of proliferative diseases |
| WO2018146199A1 (en) | 2017-02-08 | 2018-08-16 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
-
2021
- 2021-05-28 GB GBGB2107706.0A patent/GB202107706D0/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO2007044515A1 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Azetidines as mek inhibitors for the treatment of proliferative diseases |
| WO2018146199A1 (en) | 2017-02-08 | 2018-08-16 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
Non-Patent Citations (21)
| Title |
|---|
| "Genbank", Database accession no. CAA78163 |
| ANGEW CHEM. INTL. ED. ENGL., vol. 33, 1994, pages 183 - 186 |
| CARTER, P., NATURE REVIEWS IMMUNOLOGY, vol. 6, 2006, pages 343 - 357 |
| CAS , no. 391210-10-9 |
| CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628 |
| FLYNN ET AL., MOL CANCER THER, 2016 |
| HAMANN P., EXPERT OPIN. THER. PATENTS, vol. 15, no. 9, 2005, pages 1087 - 1103 |
| JANEWAY, C.TRAVERS, P.WALPORT, M.SHLOMCHIK: "Immuno Biology", 2001, GARLAND PUBLISHING |
| KOHLER ET AL., NATURE, vol. 256, 1975, pages 495 |
| KOVTUN ET AL., CANCER RES., vol. 66, no. 4, 2006, pages 2328 - 2337 |
| KS PEGGS ET AL., CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 157, 2009, pages 9 - 19 |
| LAMBERT J, CURRENT OPIN. IN PHARMACOL., vol. 5, 2005, pages 543 - 549 |
| LONBERG, CURR. OPINION, vol. 20, no. 4, 2008, pages 450 - 459 |
| MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597 |
| MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855 |
| PAYNE, G., CANCER CELL, vol. 3, 2003, pages 207 - 212 |
| SYRIGOSEPENETOS, ANTICANCER RESEARCH, vol. 19, 1999, pages 605 - 614 |
| TRAIL ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 52, 2003, pages 328 - 337 |
| WU ET AL., NATURE BIOTECH., vol. 23, no. 9, 2005, pages 1137 - 1145 |
| XIE ET AL., EXPERT. OPIN. BIOL. THER., vol. 6, no. 3, 2006, pages 281 - 291 |
| ZAMMARCHI ET AL., AACR ANNUAL MEETING, 14 April 2018 (2018-04-14) |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304223A (en) | Combination therapy | |
| IL319599A (en) | Combination therapy | |
| GB202103164D0 (en) | Therapy | |
| GB202004189D0 (en) | Combination therapy | |
| GB202002639D0 (en) | Therapy | |
| IL318268A (en) | Combination therapy | |
| GB202111288D0 (en) | Combination therapy | |
| GB202104037D0 (en) | Combination therapy | |
| GB202111035D0 (en) | Therapy | |
| GB202108303D0 (en) | Therapy | |
| GB202109373D0 (en) | Combination therapy | |
| GB202109375D0 (en) | Combination therapy | |
| GB202109377D0 (en) | Combination therapy | |
| GB202107824D0 (en) | Combination therapy | |
| GB202107709D0 (en) | Combination therapy | |
| GB202107713D0 (en) | Combination therapy | |
| GB202107706D0 (en) | Combination therapy | |
| GB202015916D0 (en) | Combination therapy | |
| GB202012161D0 (en) | Combination therapy | |
| GB202009178D0 (en) | Combination therapy | |
| GB202117706D0 (en) | Therapy | |
| GB202109893D0 (en) | PeptiBAC therapy | |
| GB202104427D0 (en) | Therapy | |
| GB202102211D0 (en) | PeptiBAC therapy | |
| GB202019218D0 (en) | Therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |